Wealthspire Advisors LLC lowered its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 23.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 88,023 shares of the biopharmaceutical company’s stock after selling 27,630 shares during the period. Wealthspire Advisors LLC’s holdings in Pfizer were worth $4,557,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of PFE. PYA Waltman Capital LLC bought a new position in Pfizer in the 4th quarter worth $31,000. Rinkey Investments bought a new position in Pfizer in the 4th quarter worth $32,000. Stuart Chaussee & Associates Inc. lifted its stake in Pfizer by 108.3% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 325 shares in the last quarter. Bivin & Associates Inc. purchased a new stake in Pfizer in the 4th quarter worth $37,000. Finally, Evolution Advisers Inc. lifted its stake in Pfizer by 309.3% in the 1st quarter. Evolution Advisers Inc. now owns 794 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 600 shares in the last quarter. Institutional investors own 66.50% of the company’s stock.
Pfizer Trading Down 1.2 %
Shares of Pfizer stock opened at $49.27 on Friday. The stock has a market cap of $276.45 billion, a PE ratio of 9.64, a price-to-earnings-growth ratio of 0.61 and a beta of 0.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. The firm has a fifty day moving average price of $51.09 and a 200 day moving average price of $51.10. Pfizer Inc. has a 1 year low of $40.94 and a 1 year high of $61.71.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, July 28th. This represents a $1.60 annualized dividend and a dividend yield of 3.25%. Pfizer’s dividend payout ratio (DPR) is 31.31%.
In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the business’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the transaction, the executive vice president now directly owns 38,146 shares in the company, valued at $1,907,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Jennifer B. Damico sold 4,218 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now directly owns 38,146 shares in the company, valued at $1,907,300. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock worth $2,075,003 over the last 90 days. 0.05% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
PFE has been the topic of several research analyst reports. SVB Leerink decreased their price target on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. The Goldman Sachs Group set a $50.00 target price on shares of Pfizer in a research report on Friday, July 29th. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research note on Tuesday, June 28th. Finally, Barclays increased their price objective on shares of Pfizer from $50.00 to $52.00 and gave the company an “equal weight” rating in a research note on Monday, August 1st. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.